The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Future directions for multiple myeloma treatment
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, gives an overview of the evolving treatment paradigm for multiple myeloma patients. Dr Martin discusses the potential development of a cure for myeloma in the future, highlighting emerging results from studies investigating CAR T-cell therapies for patients with relapsed/refractory myeloma, and the possible impact of bringing these into a frontline setting. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Research funding to institution: Sanofi, Janssen, AMGEN
Consultancy: GSK
